Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2022 07:00 ET | Source: Vaxxinity, Inc.

Vaxxinity to Participate at the Jefferies Healthcare Conference

DALLAS, June 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...
May 09, 2022 07:42 ET | Source: Vaxxinity, Inc.

Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates

DALLAS, May 09, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for...
May 05, 2022 07:00 ET | Source: Vaxxinity, Inc.

Vaxxinity to Participate at the Bank of America Securities 2022 Healthcare Conference

DALLAS, May 05, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...
May 02, 2022 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease

DALLAS, May 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an...
April 28, 2022 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease

Results from UB-312’s Part A first-in-human trials published in Movement Disorders DALLAS, April 28, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the...
April 06, 2022 16:43 ET | Source: Vaxxinity, Inc.

CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of...
March 28, 2022 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity Announces First Participant Dosed in Phase 3 Study of Next-Generation COVID-19 Vaccine Booster

Pivotal Phase 3 head-to-head study will evaluate non-inferiority of heterologous booster candidate UB-612 against authorized mRNA, adenovirus vector and inactivated virus COVID-19 vaccinesAgreement...
March 24, 2022 16:05 ET | Source: Vaxxinity, Inc.

Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates

DALLAS, March 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results...
March 21, 2022 07:00 ET | Source: Vaxxinity, Inc.

Vaxxinity Appoints Dr. Peter Powchik to Board of Directors

DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today...
February 11, 2022 09:28 ET | Source: Vaxxinity, Inc.

Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

Investigator-sponsored studies show UB-612 induces high antibody activity against multiple variants, including Alpha, Beta, Delta, Gamma and Omicron, at levels similar to or higher than approved...